ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2020, Vol. 34 ›› Issue (5): 157-162.doi: 10.6040/j.issn.1673-3770.0.2019.545
CLC Number:
| [1] Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al. Myopic maculopathy: Current status and proposal for a new classification and grading system(ATN)[J]. Prog Retin Eye Res, 2019, 69: 80-115. doi:10.1016/j.preteyeres.2018.10.005. [2] Ohno-Matsui K. What is the fundamental nature of pathologic myopia?[J]. Retina, 2017, 37(6): 1043-1048. doi:10.1097/iae.0000000000001348. [3] Kyoko OM, Yasushi I, Timothy YYL, et al. Diagnosis and treatment guideline for myopic choroidal neovascularizationdue to pathologic myopia[J]. Prog Retin Eye Res, 2018, 63:92-106. doi: 10.1016/j.preteyeres.2017.10.005. [4] Lai TY, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment[J]. Retina, 2016,36(9):1614-21. doi: 10.1097/IAE.0000000000001227. [5] Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy[J]. Am J Ophthalmol, 2015, 159(5): 877-883.e7. doi:10.1016/j.ajo.2015.01.022. [6] Danny SC Ng, Timothy YY Lai, Cheung CMG,et al. Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization[J]. Asia Pac J Ophthalmol(Phila),2017,6(6):554-560. doi: 10.22608/APO.2017308. [7] 丁雯芝, 邹俊. 病理性近视脉络膜新生血管发病机制的研究进展[J]. 眼科新进展, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274. DING Wenzhi, ZOU Jun. Research advances in pathogenesis of choroidal neovascularization of pathologic myopia[J]. Recent Advances in Ophthalmology, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274. [8] Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia[J]. Invest Ophthalmol Vis Sci, 2010, 51(7): 3721-3725. doi:10.1167/iovs.09-3493. [9] Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia[J]. Br J Ophthalmol, 2003, 87(5): 570-573. doi:10.1136/bjo.87.5.570. [10] 孙明甡, 张丰菊. 病理性近视发病机制相关研究新进展[J]. 中国实用眼科杂志, 2014(4): 393-397. doi:10.3760/cma.j.issn.1006-4443.2014.04.001. [11] Nakai K, Rogers MS, Baba T, et al. Genetic loci that control the size of laser-induced choroidal neovascularization[J]. FASEB J, 2009, 23(7): 2235-2243. doi:10.1096/fj.08-124321. [12] Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up[J]. Ophthalmology, 2003, 110(7): 1297-1305. doi:10.1016/S0161-6420(03)00461-5. [13] 占宗议, 李梓敬, 丁小燕. 病理性近视继发脉络膜新生血管诊疗现状与进展[J]. 中华眼底病杂志, 2016(1): 104-107. doi:10.3760/cma.j.issn.1005-1015.2016.01.029. ZHAN Zongyi, LI Zijing, DING Xiaoyan. Choroidal neovascularization secondary to pathologic myopia: a recent update on diagnosis and treatment[J]. Chinese Journal of Ocular Fundus Diseases, 2016(1): 104-107. doi:10.3760/cma.j.issn.1005-1015.2016.01.029. [14] Laviers H, Li JO, Grabowska A, et al. The management of macular hole retinal detachment and macular retinoschisis in pathological myopia; a UK collaborative study[J]. Eye(Lond), 2018, 32(11): 1743-1751. doi:10.1038/s41433-018-0166-4. [15] Querques L, Giuffrè C, Corvi F, et al. Optical coherence tomography angiography of myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2017, 101(5): 609-615. doi:10.1136/bjophthalmol-2016-309162. [16] Soomro T, Talks J, Medscape. The use of optical coherence tomography angiography for detecting choroidal neovascularization, compared to standard multimodal imaging[J]. Eye(Lond), 2018, 32(4): 661-672. doi:10.1038/eye.2018.2. [17] Bruyère E, Miere A, Cohen SY, et al. Neovascularization secondary to high myopia imaged by optical coherence tomography angiography[J]. Retina(Philadelphia, Pa), 2017, 37(11): 2095-2101. doi:10.1097/IAE.0000000000001456. [18] 张士胜, 廖华萍, 王康孙. 病理性近视脉络膜新生血管的激光治疗[J]. 医学综述, 2008, 14(19): 2959-2963. doi:10.3969/j.issn.1006-2084.2008.19.027. ZHANG Shisheng, LIAO Huaping, WANG Kangsun. Laser therapy of choroidal neovascularization secondary to pathologic myopia[J]. Medical Recapitulate, 2008, 14(19): 2959-2963. doi:10.3969/j.issn.1006-2084.2008.19.027. [19] Newsom RS, McAlister JC, Saeed M, et al. Transpupillary thermotherapy(TTT)for the treatment of choroidal neovascularisation[J]. Br J Ophthalmol, 2001, 85(2): 173-178. doi:10.1136/bjo.85.2.173. [20] Brancato R, Pece A, Avanza P, et al. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia[J]. Retina(Philadelphia, Pa), 1990, 10(4): 239-243. doi:10.1097/00006982-199010000-00002. [21] Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients[J]. Br J Ophthalmol, 2001, 85(9): 1041-1043. doi:10.1136/bjo.85.9.1041. [22] Uemura A. Subretinal surgery for choroidal neovascularization[J]. Nippon Ganka Gakkai Zasshi, 2000, 104(9): 611-620. [23] Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial: VIP report no. 3[J]. Ophthalmology, 2003, 110(4): 667-673. doi:10.1016/s0161-6420(02)01998-x. [24] Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up[J]. Br J Ophthalmol, 2004, 88(10): 1315-1319. doi:10.1136/bjo.2004.041624. [25] Varano M, Iacono P, Giorno P, et al. Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis[J]. Ophthalmologica, 2014, 231(4): 204-210. doi:10.1159/000357504. [26] Willis J, Morse L, Vitale S, et al. Treatment patterns for myopic choroidal neovascularization in the United States: analysis of the IRIS registry[J]. Ophthalmology, 2017, 124(7): 935-943. doi:10.1016/j.ophtha.2017.02.018. [27] Pece A, Milani P. Intravitreal aflibercept for myopic choroidal neovascularization[J]. Graefes Arch Clin Exp Ophthalmol, 2016, 254(12): 2327-2332. doi:10.1007/s00417-016-3396-9. [28] Yan M, Huang Z, Lian HY, et al. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia[J]. Acta Ophthalmol, 2019, 97(5): e813-e814. doi:10.1111/aos.13632. [29] Moon BG, Cho AR, Lee J, et al. Improved visual outcome and low recurrence with early treatment with intravitreal anti-vascular endothelial growth factor in myopic choroidal neovascularization[J]. Ophthalmologica, 2017, 237(3): 128-138. doi:10.1159/000458160. [30] Gonzalez CC, Juan RF, Jose V, et al. Long-term outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal Neovascularization[J]. Ophthalmologica, 2017,238(4):196-204. doi: 10.1159/000478030. [31] Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study[J]. Retina(Philadelphia, Pa), 2017, 37(9): 1775-1783. doi:10.1097/IAE.0000000000001421. [32] 阎静, 徐冲, 严立, 等. 雷珠单抗和PDT治疗病理性近视合并黄斑CNV的疗效比较[J]. 国际眼科杂志, 2018, 18(3): 498-501. doi:10.3980/j.issn.1672-5123.2018.3.22. YAN Jing, XU Chong, YAN Li, et al. Evaluation of Ranibizumab and PDT for patients with pathologic myopia and macular CNV[J]. International Eye Science, 2018, 18(3): 498-501. doi:10.3980/j.issn.1672-5123.2018.3.22. [33] Rishi P, Rishi E, Bhende M, et al. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre[J]. Br J Ophthalmol, 2016, 100(10): 1337-1340. doi:10.1136/bjophthalmol-2015-307802. [34] Rinaldi M, Semeraro F, Chiosi F, et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(3): 529-539. doi:10.1007/s00417-016-3498-4. [35] Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study[J]. Retina(Philadelphia, Pa), 2017, 37(9): 1775-1783. doi:10.1097/IAE.0000000000001421. [36] Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3): 682-692.e2. doi:10.1016/j.ophtha.2013.10.023. [37] Chen YX, Sharma T, Li XR, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study[J]. Retina(Philadelphia, Pa), 2019, 39(10): 1985-1994. doi:10.1097/IAE.0000000000002292. |
| [1] | ZHANG Taoran, WANG Wei, LI Mingming, HUANG Yingxiang. Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 68-71. |
| [2] | HUA Hongli, LI Song,TAO Zezhang. Research progress of artificial intelligence in the diagnosis and treatment of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 113-119. |
| [3] | LIU Zhai，,YING Minzheng. Research progress on circRNAs in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 105-112. |
| [4] | HUANG Yongwang, FU Dehui. Category and disease classification of voice medicine [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 1-4. |
| [5] | . Superior semicircular canal dehiscence syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 89-96. |
| [6] | ObjectiveTo discuss the early diagnosis and multidisciplinary diagnosis and treatment of neovascular glaucoma in ocular ischemic syndrome. MethodsThe medical records of a 54-year-old male patient with cerebral infarction who presented with right-eye vision loss that had persisted for a week were reviewed. After slit-lamp examination and fluorescence angiography, he was diagnosed with ocular ischemic syndrome(OIS)complicated by neovascular glaucoma in the right eye and treated with intravitreal injection of anti-VEGF drugs and panretinal photocoagulation. ResultsAfter three months of treatment, the right-eye iris neovascularization subsided, and the intraocular pressure was controlled within normal limits. ConclusionOcular ischemia is often missed or misdiagnosed by ophthalmologists, neurologists, cardiologists, and vascular surgeons due to its insidious onset and complex clinical manifestations. Therefore, the establishment of multidisciplinary diagnosis and treatment can improve the prognosis of OIS patients.. Neovascular glaucoma in ocular ischemic syndrome: a case report and literature reviewQIN Shuqi1, WANG Luping1, JIANG Bin2, WANG Yanling1 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, China; 2. Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 53-55. |
| [7] | To explore the genesis, clinical diagnosis, treatment, and prevention mechanisms of the formation of stones within the nasal cavity and sinus as well as measures toreduce the rate of clinical misdiagnosis. MethodsA comprehensive analysis was conducted on six patients with nasal and sinus calculi who visited the hospital between April 2012 and November 2017. The etiology, pathology, clinical diagnosis, differential diagnosis, treatment, prevention, and complication management of the disease were summarized for each patient. ResultFive patients underwent surgery for the removal of stones from the nasal cavity and sinus under general anesthesia. Nasal endoscopy was also performed for the assessment of the related sinus passages. One patient recovered upon nasal irrigation and anti-inflammation treatment. All the patients were followed up for six months and the mucosal layer within the operation area that was epithelialized, recovered well. The symptoms disappeared without any additional complications. ConclusionNasal endoscopy in combination with the assessment of clinical manifestation and imaging are conducive to the diagnosis of the disease. Together, these could develop into an effective treatment regimen for nasal cavity and sinusoidal lithiasis.. Clinical experience in diagnosis and treatment of stone in nasal cavity and sinusZHAI Xingyou1, HOU Junsheng2, LI Xinjian1, WANG Xin1, XIE Yingli1, WANG Wenjia1 1. Department of Otorhinolaryngology Head and Neck Surgery, Hainan Hospital, General Hospital of PLA, Hainan Province Otorhinolaryngology Head and Neck Surgery Clinical Medical Research Center, Sanya 572013, Hainan, China; 2. Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Henan University, Kaifeng 475001, Henan, ChinaAbstract:Objective [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 92-96. |
| [8] | JIANG Zhenhua, ZHANG Lijun, LI Ying, XIAO Yanqin, LI Chao, SHI Bo, ZHANG Guiying, XU Bin, DENG Wei, LUO Gang, LUO Jifang, LIU Guoqi. Epidemic control practices of an otolaryngology-head and neck surgery ward in an area with non-high incidence of COVID-19 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(2): 93-98. |
| [9] | Taisheng CHEN, Wei WANG, Kaixu XU, Peng LIN. Thoughts on benign paroxysmal positional vertigo and its diagnosis and treatment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 1-5. |
| [10] | YAN Zhigang, ZHANG Huihui, YU Dan, LIU Yan, WEN Lianji, WANG Di. Diagnosis and treatment of cognitive deficits in adult patients with obstructive sleep apnea hypopnea syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 155-161. |
| [11] | CHEN Lixiao, JIANG Rui, YU Ziwei. Narrow-band imaging in diagnosis and treatment of tumors of the pharynx and larynx [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 104-108. |
| [12] | ZHANG Ying-chun, DU Xiang-ge, YAN Xin, WANG Cui, ZHAO Bo-jun. Effect of nicotine on human RPE cells and HUVECs [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(2): 74-80. |
| [13] | GONG Bin, FAN Chuan-feng, WANG Yu. Anti VEGF drugs(lucentis) to treat different courses of wet age-related maculardegeneration (62 cases report) [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(5): 58-61. |
| [14] | CAO Zhong-liang1, XU Xing-xing2. Diagnosis and treatment of reflux throat pharyngitis with helicobacter pylori infection [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(1): 58-60. |
|